Table 1.
Selected clinical trials using Lactobacillus reuteri for H. pylori eradication treatment.
| Treatment | Probiotic(s) | Eradication rate | Probiotic efficacy | References |
|---|---|---|---|---|
| Triple therapy, Omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, 14 d |
L. reuteri ATCC PTA 6475, L. reuteri DSM 17938, 14 d during therapy + further 14 d, Control |
74.3% (26/35) 65.7% (23/35) |
Non-significant increase of eradication rate with improved GSRS score and reduction of side effects (taste disorder, diarrhea) | Emara et al., 2014 |
| Three-phase study; pre-eradication (1–28 d), eradication (29–35 d), follow-up (36–96 d), Triple therapy |
L. reuteri ATCC PTA 6475, L. reuteri DSM 17938, Control |
75% (37/50) 65.9% (33/50) |
Non-significant increase of eradication rate but no difference in GSRS score | Francavilla et al., 2014 |
| Pantoprazole 20 mg, 8 weeks | L. reuteri, 8 weeks | 14.2% (3/21) | Good tolerability with no side effects | Dore et al., 2014 |
| Levofloxacin 500 mg, esomeprazole 20 mg, amoxicillin 1 g, 7 d | L. reuteri, during therapy + further 7 d Control | 80% (36/45) 62.2% (28/45) |
Significantly increase of eradication rates and reduction of side effects (Nausea, diarrhea) | Ojetti et al., 2012 |
| Omeprazole 1 mg/kg, amoxicillin 50 mg/kg, clarithromycin15 mg/kg, 7 d | L. plantarum, L. reuteri, L. casei subsp. rhamnosus, B. infantis, and B. longum, L. acidophilus, L. salivarius, S. thermophilus, L. sporogenes, during therapy Control | 82.2% (30/34) 76.4% (26/34) |
Non-significant increase of eradication rates; significant reduction of side effects (epigastric pain, nausea, vomiting, diarrhea) | Tolone et al., 2012 |
| Pantoprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, Triple therapy, 7 d Sequential regimen, 10 d | L. reuteri ATCC55730, during therapy + further 7 or 10 d |
63% (52/83) 88% (73/83) |
Significantly higher eradication rate and reduction of side effects in sequential regimen | Efrati et al., 2012 |
| Sequential therapy (Details not describe) | L. reuteri ATCC55730, 8 weeks Control | 33.8 ± 15% (33) 35.8 ± 15.5% (33) |
Significant decrease in Gastrointestinal Symptom | Francavilla et al., 2008 |
| Triple therapy (Details not describe) | L. reuteri, 7 d Control | 63% 53% |
Lowest incidence of side-effects | Scaccianoce et al., 2008 |
| No drug | L. reuteri SD2112, 8 weeks | 69.7 ± 4% (33) | Significant reduction of 13C-UBT | Imase et al., 2007 |
| Omeprazole 1 mg/kg, amoxicillin 50 mg/kg, clarithromycin15 mg/kg, sequential therapy, 10 d | L. reuteri ATCC55730 (SD2112) Control | 85% (17/20) 80% (16/20) |
Significant reduction of GSRS score | Lionetti et al., 2006 |
GSRS, Gastrointestinal Symptom Rating Scale; 13C-UBT; 13C Urea Breath Test.